EP44 Taking eosinophilia more seriously

Abstract Background Asymptomatic eosinophilia is common in migrants and travellers returning from the tropics, and helminth infection is the most common identifiable cause. Most helminth infections have a benign course, but some carry a risk of serious disease which is relevant to the rheumatologist...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 59; no. Supplement_2
Main Authors Rutter-Locher, Zoe, Galloway, James, Menon, Bina, Goodman, Anna
Format Journal Article
LanguageEnglish
Published Oxford University Press 01.04.2020
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background Asymptomatic eosinophilia is common in migrants and travellers returning from the tropics, and helminth infection is the most common identifiable cause. Most helminth infections have a benign course, but some carry a risk of serious disease which is relevant to the rheumatologist as administration of immunosuppression can trigger severe reactions such as the potentially fatal hyper infection syndrome in strongyloidiasis. Helminth infections are of increasing relevance in an era of growing migration from endemic regions. A recent audit performed at a central London hospital in HIV outpatients found that of those patients with asymptomatic eosinophilia that were investigated, 28.6% had serological evidence of strongyloidiasis. Unexplained eosinophilia should be evaluated prior to starting immunosuppressive medications, especially in those who have lived in regions endemic for helminth infections. In 2010 the British Infection Society (BIS) published guidelines on the investigation of migrants and returning travellers with asymptomatic eosinophilia. We set out to establish how often our unit investigated unexplained eosinophilia prior to initiating immunosuppressive medication. Methods All patients attending rheumatology outpatients at our centre were screened and included if they had a recorded eosinophilia of ≥ 0.8 X109/L between December 2016 to December 2018. Patients were excluded if they did not have a sustained eosinophilia ≥0.8 X109/L > 1 year or if another documented diagnosis was recognised as the cause of eosinophilia. Investigation of asymptomatic eosinophilia was compared to the best practice set out in British Infection Society guideline. Results 109 patients fulfilled the inclusion criteria. 64 patients did not have a sustained eosinophilia > 1 year and 16 had an alternate diagnosis to explain eosinophilia and so were excluded. The remaining 29 patients were included. 13 patients were male and 16 female. 16 (55%) had a diagnosis of rheumatoid arthritis. 19 (66%) had an eosinophil count > 1 X109/L and 7 (24%) > 2 X109/L. Despite this, eosinophilia was only noted in documentation for 4 (14%) patients. Five (17%) patients had a travel history documented and 4 of them had travelled to the tropics. 3 (10%) patients were investigated for eosinophilia and only 1 (3%) was investigated fully according to the BIS guideline. 14 (48%) patients were on bDMARDs and a further 6 (21%) were on cDMARDs. Of the 14 (48%) on bDMARDS, 7 had ethnic origin in the tropics. Median eosinophil count was 1.2 x109/L. One had travel history taken. All had a negative HIV test. None of the patients on biological therapy had investigations for eosinophilia. Conclusion This study confirms the local lack of awareness of eosinophilia. Most patients with unexplained eosinophilia were not identified or investigated, even prior to administration of immunosuppressive medication. With a growing migrant population, the likelihood of serious consequences of ignoring eosinophilia are rising. Disclosures: Z. Rutter-Locher: None. J. Galloway: None. B. Menon: None. A. Goodman: None.
AbstractList Abstract Background Asymptomatic eosinophilia is common in migrants and travellers returning from the tropics, and helminth infection is the most common identifiable cause. Most helminth infections have a benign course, but some carry a risk of serious disease which is relevant to the rheumatologist as administration of immunosuppression can trigger severe reactions such as the potentially fatal hyper infection syndrome in strongyloidiasis. Helminth infections are of increasing relevance in an era of growing migration from endemic regions. A recent audit performed at a central London hospital in HIV outpatients found that of those patients with asymptomatic eosinophilia that were investigated, 28.6% had serological evidence of strongyloidiasis. Unexplained eosinophilia should be evaluated prior to starting immunosuppressive medications, especially in those who have lived in regions endemic for helminth infections. In 2010 the British Infection Society (BIS) published guidelines on the investigation of migrants and returning travellers with asymptomatic eosinophilia. We set out to establish how often our unit investigated unexplained eosinophilia prior to initiating immunosuppressive medication. Methods All patients attending rheumatology outpatients at our centre were screened and included if they had a recorded eosinophilia of ≥ 0.8 X109/L between December 2016 to December 2018. Patients were excluded if they did not have a sustained eosinophilia ≥0.8 X109/L > 1 year or if another documented diagnosis was recognised as the cause of eosinophilia. Investigation of asymptomatic eosinophilia was compared to the best practice set out in British Infection Society guideline. Results 109 patients fulfilled the inclusion criteria. 64 patients did not have a sustained eosinophilia > 1 year and 16 had an alternate diagnosis to explain eosinophilia and so were excluded. The remaining 29 patients were included. 13 patients were male and 16 female. 16 (55%) had a diagnosis of rheumatoid arthritis. 19 (66%) had an eosinophil count > 1 X109/L and 7 (24%) > 2 X109/L. Despite this, eosinophilia was only noted in documentation for 4 (14%) patients. Five (17%) patients had a travel history documented and 4 of them had travelled to the tropics. 3 (10%) patients were investigated for eosinophilia and only 1 (3%) was investigated fully according to the BIS guideline. 14 (48%) patients were on bDMARDs and a further 6 (21%) were on cDMARDs. Of the 14 (48%) on bDMARDS, 7 had ethnic origin in the tropics. Median eosinophil count was 1.2 x109/L. One had travel history taken. All had a negative HIV test. None of the patients on biological therapy had investigations for eosinophilia. Conclusion This study confirms the local lack of awareness of eosinophilia. Most patients with unexplained eosinophilia were not identified or investigated, even prior to administration of immunosuppressive medication. With a growing migrant population, the likelihood of serious consequences of ignoring eosinophilia are rising. Disclosures: Z. Rutter-Locher: None. J. Galloway: None. B. Menon: None. A. Goodman: None.
Author Goodman, Anna
Menon, Bina
Galloway, James
Rutter-Locher, Zoe
Author_xml – sequence: 1
  givenname: Zoe
  surname: Rutter-Locher
  fullname: Rutter-Locher, Zoe
  organization: Rheumatology and Lupus, Guy's and St Thomas' NHS trust, London, UNITED KINGDOM
– sequence: 2
  givenname: James
  surname: Galloway
  fullname: Galloway, James
  organization: Rheumatology, King's College Hospital NHS Trust, London, UNITED KINGDOM
– sequence: 3
  givenname: Bina
  surname: Menon
  fullname: Menon, Bina
  organization: Rheumatology and Lupus, Guy's and St Thomas' NHS trust, London, UNITED KINGDOM
– sequence: 4
  givenname: Anna
  surname: Goodman
  fullname: Goodman, Anna
  organization: Infectious Diseases, Guy's and St Thomas' NHS trust, London, UNITED KINGDOM
BookMark eNqNj71qwzAUhUVJoUnad_DawcmVrmwrYwnpDwTaIZ2FJMuJGtsyUj14K_RN-yR1SSgdO53Dge_ANyOT1reWkITCgsIKl-Fg-0a9-9rvh-XRKjWuC-B4QaaU5ywFRDb57YxfkVmMbwCQURRTcrt54fzr43Onjq7dJ9ZH1_ru4GqnksYHm0QbnO9jPVyTy0rV0d6cc05e7ze79WO6fX54Wt9tU0M5YipMJpgpCxAatCh5YTOFmGeIGQNtOOVa6ZJyVkJeVZpZasZR0GI1goXOcE7E6dcEH2OwleyCa1QYJAX5oyz_KsuzshyVRxRPqO-7_1PffqljGg
ContentType Journal Article
Copyright The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020
Copyright_xml – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020
DBID AAYXX
CITATION
DOI 10.1093/rheumatology/keaa109.043
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate British Society for Rheumatology Annual Conference 2020 Abstracts
EISSN 1462-0332
ExternalDocumentID 10_1093_rheumatology_keaa109_043
10.1093/rheumatology/keaa109.043
GroupedDBID ---
-E4
.2P
.I3
.XZ
.ZR
08P
0R~
18M
29P
2WC
354
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAJKP
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IOX
J21
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NU-
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
RIG
ROL
ROX
RUSNO
RW1
RXO
SV3
TCURE
TEORI
TJX
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
ZY1
~91
AAYXX
ABEJV
AHMMS
CITATION
ID FETCH-LOGICAL-c1433-8c582cd708b0b8d47e5a336533520bc414babd142d06ffb2e1cc418179c587b53
ISSN 1462-0324
IngestDate Fri Dec 06 02:48:59 EST 2024
Wed Aug 28 03:18:42 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_2
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1433-8c582cd708b0b8d47e5a336533520bc414babd142d06ffb2e1cc418179c587b53
OpenAccessLink https://academic.oup.com/rheumatology/article-pdf/59/Supplement_2/keaa109.043/33102400/keaa109.043.pdf
ParticipantIDs crossref_primary_10_1093_rheumatology_keaa109_043
oup_primary_10_1093_rheumatology_keaa109_043
PublicationCentury 2000
PublicationDate 20200401
2020-04-01
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: 20200401
  day: 01
PublicationDecade 2020
PublicationTitle Rheumatology (Oxford, England)
PublicationYear 2020
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
SSID ssj0005138
Score 2.3544645
Snippet Abstract Background Asymptomatic eosinophilia is common in migrants and travellers returning from the tropics, and helminth infection is the most common...
SourceID crossref
oup
SourceType Aggregation Database
Publisher
Title EP44 Taking eosinophilia more seriously
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA46QXwRrzhv9MEXmZ1tk7bZo5fpvCKywfClJGmKoFiRDS9Pgv_UX-JJk3WZDLy8lC1sp03PR3LOyTnfQWiLM4lho2ZuKLMAHBS_4TbAsndZFoJxEkhKMxXQv7iMWh1y2g271ompqi7p8bp4G1tX8h-twhjoVVXJ_kGzpVAYgM-gX7iChuH6Kx03rwgx2QoUt4u-UjWZg_efP6o4CaupLNqaehTw7-9HDnCvb2UfjFXNwKQoR18GWe6mrYcVIrgumlm75_lAwTd5CYdjdXD_zF7LjNtSg_JBH-jvmwbdmoU_T03IVTE32yGHwLMyVfQqSaLA9bAufq5LewyPLK2G7FtDqGhTWsQ8k2Ds4q2JrZ6s-cPXO8mYr0hFNZvTKGP2t52szC_UJ-s4sWUlRlICkibRlCJOVL0WDk_OhilBftH5vJyeyfwCSbu2pF3rmUbMGVUiaVkn7Tk0a9wKZ09jZB5NyIcFNH1hEicW0baCyuf7hwaJY4PEUSBxSpAsoc5Rs33Qck2XDFeArYtdKkIaiDT2KPc4TUksQ4ZxFKpiOo8L4hPOeOqTIPWiLOOB9AUMUliI4Y8xD_EyqgAg5ApyREphu_MjGqaSCHC7eJRFccwE3EdGTFSRP5hs8qjJUJKfXnUV7cBb-fXPV_9xizU0M0TpOqr0nvpyA0zFHt8s9PsFijRsWA
link.rule.ids 314,780,784,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EP44%E2%80%83Taking+eosinophilia+more+seriously&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Rutter-Locher%2C+Zoe&rft.au=Galloway%2C+James&rft.au=Menon%2C+Bina&rft.au=Goodman%2C+Anna&rft.date=2020-04-01&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=59&rft.issue=Supplement_2&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaa109.043&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keaa109_043
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon